Many experts didn't expect Biogen to pursue phase 4 study this fast since if my memory is correct FDA said they need to start conducting post approval study by like 2029? I guess the drama about its efficacy and its high price tag and the burden it's putting on their medicare system is putting pressure on Biogen.
Size of this trial will be almost as big as phase 3... wonder how much revenue CGS can get out of this?
Ann: Notification regarding unquoted securities - CGS, page-34
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.5¢ |
Change
-0.005(0.52%) |
Mkt cap ! $166.6M | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | 97.0¢ | 96.5¢ | $30.28K | 31.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61912 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 1158 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CGS (ASX) Chart |